In the search for novel Gram-negative agents, we performed a comprehensive search of the AstraZeneca collection and identified a tetrahydropyran-based matrix metalloprotease (MMP) inhibitor that demonstrated nanomolar inhibition of UDP-3-O-(acyl)-N-acetylglucosamine deacetylase (LpxC). Crystallographic studies in Aquifex aeolicus LpxC indicated the tetrahydropyran engaged in the same hydrogen bonds and van der Waals interactions as other known inhibitors. Systematic optimization of three locales on the scaffold provided compounds with improved Gram-negative activity. However, the optimization of LpxC activity was not accompanied by reduced inhibition of MMPs. Comparison of the crystal structure of the native product, UDP-3-O-(acyl)-glucosamine, in Aquifex aeolicus to the structure of a tetrahydropyran-based inhibitor indicates pathways for future optimization.KEYWORDS: Antibacterial, LpxC, Gram-negative bacteria, MMP, hydrophobe, Pseudomonas aeruginosa, Aquifex aeolicus T he need for new antibacterials active against Gram-negative bacteria is becoming critical. Current therapies are becoming ineffective due to increasing resistance, leaving healthcare practicioners with limited treatment options for serious bacterial infections. 1−3 To compound the issue, the presence of an additional cell membrane, incorporating lipopolysaccharide (LPS) in the outer leaflet, confers an intrinsic degree of resistance to Gram-negative pathogens. 4−6 The presence of the LPS layer, in addition to promiscuous efflux pumps, prevents agents effective at killing Gram-positive bacteria from penetrating the Gram-negative cellular envelope.UDP-3-O-(acyl)-N-acetylglucosamine deacetylase (LpxC) has become the focus of a number of programs aimed at the development of novel Gram-negative agents. 7 LpxC is a cytosolic zinc metallo-enzyme that catalyzes the deacetylation of UDP-3-O-(acyl)-N-acetylglucosamine, the first nonreversible step in the biosynthesis of lipid A, the main component and the substrate to which LPS is attached in the outer membrane of most Gramnegative bacteria. 8,9 Because the biosynthesis of lipid A is essential for maintenance of the outer membrane, LpxC is an attractive target for the development of new agents.A number of inhibitors of LpxC have been reported in the literature. 10−15 One of the most well documented inhibitors is CHIR-090 (1, Figure 1). 16−18 Key structural features of CHIR-090, which are consistent in other reported inhibitors, are a zincbinding group (hydroxamate) and a hydrophobic tail (hydrophobe), which sits in a narrow hydrophobic tunnel, usually occupied by the fatty acid tail of the natural substrate. The major difference between the various classes of inhibitors is the core that links the hydroxamate to the hydrophobe. CHIR-090 contains a threonine-based core, which has been shown to engage in a key hydrogen bond with Lys238 in Pseudomonas aeruginosa (P. aeruginosa) LpxC. Pfizer has reported on a series of methylsulfone-based inhibitors, which also take advantage of this hydrogen bon...